DK2760507T3 - Lægemiddelfremføringsanordning og fremgangsmåde til samling af en lægemiddelfremføringsanordning - Google Patents
Lægemiddelfremføringsanordning og fremgangsmåde til samling af en lægemiddelfremføringsanordning Download PDFInfo
- Publication number
- DK2760507T3 DK2760507T3 DK12762612.5T DK12762612T DK2760507T3 DK 2760507 T3 DK2760507 T3 DK 2760507T3 DK 12762612 T DK12762612 T DK 12762612T DK 2760507 T3 DK2760507 T3 DK 2760507T3
- Authority
- DK
- Denmark
- Prior art keywords
- piston rod
- cartridge
- distance
- proximal end
- housing
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title claims description 34
- 238000000034 method Methods 0.000 title claims description 19
- 229940079593 drug Drugs 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 40
- 238000005259 measurement Methods 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims 7
- 238000010168 coupling process Methods 0.000 claims 7
- 238000005859 coupling reaction Methods 0.000 claims 7
- 238000006073 displacement reaction Methods 0.000 claims 2
- 238000012840 feeding operation Methods 0.000 claims 2
- 230000009849 deactivation Effects 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 54
- 108010011459 Exenatide Proteins 0.000 description 50
- 229960001519 exenatide Drugs 0.000 description 50
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 239000012634 fragment Substances 0.000 description 11
- 230000037452 priming Effects 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000717 retained effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000003466 welding Methods 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31536—Blocking means to immobilize a selected dose, e.g. to administer equal doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3103—Leak prevention means for distal end of syringes, i.e. syringe end for mounting a needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49764—Method of mechanical manufacture with testing or indicating
- Y10T29/49778—Method of mechanical manufacture with testing or indicating with aligning, guiding, or instruction
- Y10T29/4978—Assisting assembly or disassembly
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Claims (15)
1. Lægemiddelfremføringsanordning (1), der omfatter: - et hus (4), der omfatter en distal ende og en proksimal ende, - en patron (3), der er beregnet og indrettet til at indeholde mindst én dosis af et lægemiddel (16), en spuns (5), der er bevægeligt anbragt i patronen (3), hvor spunsen (5) i en starttilstand af anordningen (1) er anbragt i en proksimal endeposition i forhold til patronen (3), - en stempelstang (9), der er beregnet og indrettet til at bevæge spunsen (5) i den distale retning i forhold til patronen (3) til fremføring af en dosis af lægemidlet (16), hvilken anordning (1) omfatter en mekanisme, der fungerer, således at stempelstangen (9), efter at en dosisfremføringsoperation er gennemført, bevæges i den proksimale retning i forhold til spunsen (5) med en tilbageføringsafstand (D) , der er kendetegnet ved, at en afstand mellem en distal ende af stempelstangen (9) og en proksimal ende af spunsen (5) i starttilstanden er større end nul, hvor afstanden mellem stempelstangen (9) og spunsen (5) i starttilstanden defineres af tilbagetrækningsafstanden (D).
2. Anordning ifølge krav 1, der yderligere omfatter en aktueringsdel (14), der er bevægelig i forhold til huset (4), hvor aktueringsdelen (14) er bevægelig mellem en første position og en anden position, og hvor bevægelse af aktueringsdelen (14) til forskydning fra den første position til den anden position overføres til stempelstangen (9) til forskydning af stempelstangen (9) med tilbageføringsafstanden (D).
3. Anordning ifølge krav 1 eller krav 2, hvor tilbageføringsafstanden (D) er større end eller lig med afstanden mellem den distale ende af stempelstangen (9) og den proksimale ende af spunsen (5) i starttilstanden.
4. Anordning ifølge krav 2 eller krav 3, hvor aktueringsdelen (14) er yderligere bevægelig mellem den anden position og en tredje position, hvor aktueringsdelen (14) placeres, efter at en dosisindstillingsoperation er gennemført, hvor den tredje position er anbragt mere proksimalt i forhold til huset (4) end den anden position.
5. Anordning ifølge et hvilket som helst af kravene 2 til 4, der omfatter en fjederdel (15), der er monteret i huset (4), hvilken fjederdel (15) er konfigureret og anbragt, så den udøver en kraft på aktueringsdelen (14) til bevægelse af aktueringsdelen (14) fra den første position til den anden position til derved bevægelse af stempelstangen (9) proksimalt med tilbageføringsafstanden (D) .
6. Anordning ifølge krav 5, hvor tilbageføringsafstanden (D) ligger i intervallet fra 0,1 til 1,0 mm.
7. Anordning ifølge krav 5 eller krav 6, hvor tilbageføringsafstanden (D) er mindre end den afstand, hvormed stempelstangen (9) bevæges distalt under en dosisfremføringsoperation.
8. Anordning ifølge et hvilket som helst af ovennævnte krav, hvor stempelstangen (9) er konfigureret, således at den aksiale dimension af stempelstangen (9) kan varieres.
9. Fremgangsmåde til samling af en lægemiddelfremføringsanordning (1), hvilken fremgangsmåde omfatter følgende trin: A) tilvejebringelse af en patronenhed, der omfatter en patron (3), der indeholder mindst én dosis af et lægemiddel (16), en spuns (5), der er bevægeligt anbragt i patronen (3), B) tilvejebringelse af en drivenhed, der kan forbindes til patronenheden, hvilken drivenhed omfatter en stempelstang (9) og en mekanisme, hvor mekanismen er konfigureret til at bevæge stempelstangen (9) med en tilbageføringsafstand (D), når mekanismen skifter fra en aktiveret tilstand til en deaktiveret tilstand, C) aktivering af mekanismen, der er kendetegnet ved, at følgende trin udføres: D) måling af positionen af den proksimale ende af spunsen (5) i forhold til et forudbestemt referencepunkt på patronenheden, E) måling af positionen af den distale ende af stempelstangen (9) i forhold til et forudbestemt referencepunkt på drivenheden, F) udledning ud fra resultaterne af målingerne udført i trin D) og E) af information, der indikerer en relativ position af den distale ende af stempelstangen (9) og den proksimale ende af spunsen (5), når patronholderen og huset er forbundet, G) deaktivering af mekanismen, således at stempelstangen (9) forskydes med tilbageføringsafstanden (D), H) kobling af patronenheden og drivenheden til hinanden, således at stempelstangen (9) og spunsen (5) anbringes i en startafstand fra hinanden, når mekanismen er deaktiveret.
10. Fremgangsmåde ifølge krav 9, hvor udledning af information omfatter bestemmelse ud fra resultaterne af målingerne af en koblingsposition til kobling af patronenheden og drivenheden, således at hvis enhederne kobles ved koblingen i koblingspositionen, anbringes stempelstangen (9) og spunsen (5) i startafstanden fra hinanden, når mekanismen er deaktiveret.
11. Fremgangsmåde ifølge krav 9 eller krav 10, hvor koblingen er en svejsesamling.
12. Fremgangsmåde ifølge krav 9, hvor udledning af information omfatter bestemmelse ud fra resultaterne af målingerne af en relativ position af den proksimale ende af spunsen (5) og den distale ende af stempelstangen (9), hvis patronenheden og drivenheden kobles ved hjælp af koblingsmidlet, der er tilvejebragt på patronenheden og drivenheden.
13. Fremgangsmåde ifølge krav 12, der yderligere omfatter trinet: kontrol af, om den relative position af den proksimale ende af spunsen (5) og den distale ende af stempelstangen (9) svarer til en forudbestemt relativ position af den proksimale ende af spunsen (5) og den distale ende af stempelstangen (9).
14. Fremgangsmåde ifølge krav 13, der yderligere omfatter trinet: hvis den relative position ikke svarer til den forudbestemte relative position, modificering af den aksiale dimension af stempelstangen (9), således at den relative position svarer til den forudbestemte relative position.
15. Fremgangsmåde ifølge krav 13 eller krav 14, hvor den forudbestemte relative position vælges, således at startafstanden mellem den proksimale ende af spunsen (5) og den distale ende af stempelstangen (9) er lig med eller lidt større end nul, når anordningen (1) er blevet samlet, og mekanismen er aktiveret.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11183300 | 2011-09-29 | ||
| PCT/EP2012/069032 WO2013045527A1 (en) | 2011-09-29 | 2012-09-27 | Drug delivery device and method for a drug delivery device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2760507T3 true DK2760507T3 (da) | 2016-08-01 |
Family
ID=46924450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12762612.5T DK2760507T3 (da) | 2011-09-29 | 2012-09-27 | Lægemiddelfremføringsanordning og fremgangsmåde til samling af en lægemiddelfremføringsanordning |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9707352B2 (da) |
| EP (1) | EP2760507B8 (da) |
| JP (1) | JP6251172B2 (da) |
| AR (1) | AR088084A1 (da) |
| CA (1) | CA2848181A1 (da) |
| DK (1) | DK2760507T3 (da) |
| ES (1) | ES2581503T3 (da) |
| HU (1) | HUE029364T2 (da) |
| PL (1) | PL2760507T3 (da) |
| WO (1) | WO2013045527A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2414775B (en) | 2004-05-28 | 2008-05-21 | Cilag Ag Int | Releasable coupling and injection device |
| GB2414400B (en) | 2004-05-28 | 2009-01-14 | Cilag Ag Int | Injection device |
| GB2414402B (en) | 2004-05-28 | 2009-04-22 | Cilag Ag Int | Injection device |
| GB2424836B (en) | 2005-04-06 | 2010-09-22 | Cilag Ag Int | Injection device (bayonet cap removal) |
| GB2425062B (en) | 2005-04-06 | 2010-07-21 | Cilag Ag Int | Injection device |
| US20110098656A1 (en) | 2005-09-27 | 2011-04-28 | Burnell Rosie L | Auto-injection device with needle protecting cap having outer and inner sleeves |
| GB2438591B (en) | 2006-06-01 | 2011-07-13 | Cilag Gmbh Int | Injection device |
| GB2461085B (en) | 2008-06-19 | 2012-08-29 | Cilag Gmbh Int | Injection device |
| US8986259B2 (en) * | 2010-03-31 | 2015-03-24 | Sanofi-Aventis Deutschland Gmbh | Piston rod assembly for a drug delivery device |
| US10201662B2 (en) * | 2013-04-10 | 2019-02-12 | Sanofi | Injection device and assembly method |
| GB2515032A (en) | 2013-06-11 | 2014-12-17 | Cilag Gmbh Int | Guide for an injection device |
| GB2515038A (en) | 2013-06-11 | 2014-12-17 | Cilag Gmbh Int | Injection device |
| GB2517896B (en) | 2013-06-11 | 2015-07-08 | Cilag Gmbh Int | Injection device |
| GB2515039B (en) | 2013-06-11 | 2015-05-27 | Cilag Gmbh Int | Injection Device |
| CN107635527B (zh) | 2015-03-10 | 2021-04-23 | 里珍纳龙药品有限公司 | 无菌刺穿系统和方法 |
| KR102546986B1 (ko) * | 2015-03-23 | 2023-06-26 | 사노피-아벤티스 도이칠란트 게엠베하 | 주사 장치를 위한 하우징 및 하우징 구성요소들의 상호연결 |
| US10485927B2 (en) | 2015-07-01 | 2019-11-26 | Novo Nordisk A/S | Method for assembling a drug delivery device and drug delivery device formed by the method |
| KR102540409B1 (ko) | 2017-05-05 | 2023-06-09 | 리제너론 파아마슈티컬스, 인크. | 자동 주사기 |
| CA3175774A1 (en) | 2017-10-16 | 2019-04-25 | Becton, Dickinson And Company | Spacer assembly for drug delivery device |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4492576A (en) * | 1982-06-15 | 1985-01-08 | Dragan William B | Dental syringe and method of packaging and dispensing a dental material |
| US5279585A (en) | 1992-02-04 | 1994-01-18 | Becton, Dickinson And Company | Medication delivery pen having improved dose delivery features |
| US5584815A (en) * | 1993-04-02 | 1996-12-17 | Eli Lilly And Company | Multi-cartridge medication injection device |
| US5514097A (en) * | 1994-02-14 | 1996-05-07 | Genentech, Inc. | Self administered injection pen apparatus and method |
| US5688251A (en) * | 1995-09-19 | 1997-11-18 | Becton Dickinson And Company | Cartridge loading and priming mechanism for a pen injector |
| GB0304823D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| GB0304822D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| AU2004266131C1 (en) * | 2003-08-12 | 2010-12-16 | Eli Lilly And Company | Medication dispensing apparatus with triple screw threads for mechanical advantage |
| DE10351596B4 (de) * | 2003-11-05 | 2007-10-11 | Tecpharma Licensing Ag | Autoinjektor mit variabler Dosis |
| HUE045180T2 (hu) * | 2004-03-30 | 2019-12-30 | Lilly Co Eli | Gyógyszeradagoló készülék az utolsó adag beadása által aktivált rugós zárolófunkcióval |
| US20080287883A1 (en) * | 2004-12-01 | 2008-11-20 | Novo Nordisk A/S | Injection Device |
| TWI294782B (en) * | 2006-01-27 | 2008-03-21 | Bencha Internat Group Inc | Medically safety injector with a collapsable plunger combination thereof |
| EP1923083A1 (en) * | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Drive mechanisms for use in drug delivery devices |
| US7627572B2 (en) * | 2007-05-02 | 2009-12-01 | Mypoints.Com Inc. | Rule-based dry run methodology in an information management system |
| PL2703020T3 (pl) * | 2008-01-28 | 2015-05-29 | Novo Nordisk As | Urządzenie iniekcyjne do wykonywania iniekcji medycznych |
| TWI555546B (zh) * | 2008-12-02 | 2016-11-01 | 賽諾菲阿凡提斯德意志有限公司 | 藥物傳輸裝置及其操作方法 |
| EP2193817A1 (en) * | 2008-12-02 | 2010-06-09 | Sanofi-Aventis Deutschland GmbH | Drive assembly suitable for use in a medication delivery device and medication delivery device |
| BRPI1016143A2 (pt) * | 2009-04-30 | 2016-04-19 | Sanofi Aventis Deutschland | conexao axialmente ajustavel de haste do pistao para mecanismo de cionamento de um dispositivo de liberacao de medicamento |
| EP2482872B2 (en) * | 2009-09-30 | 2019-12-11 | Sanofi-Aventis Deutschland GmbH | Method for assembling a drug delivery device, assembly for a drug delivery device and piston rod for a drug delivery device |
| JP5768052B2 (ja) | 2009-09-30 | 2015-08-26 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 再設定可能な薬物送達デバイス |
| JP5756470B2 (ja) | 2009-09-30 | 2015-07-29 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 再設定可能な駆動アセンブリ及び薬物送達デバイス |
| AU2010311456B2 (en) * | 2009-10-30 | 2014-10-23 | Sanofi-Aventis Deutschland Gmbh | Drug delivery devices and method of assembly |
| EP2512561B1 (en) | 2009-12-15 | 2016-04-13 | SHL Group AB | Medicament delivery device |
| CA2793032A1 (en) * | 2010-03-16 | 2011-03-16 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device |
| US8986259B2 (en) * | 2010-03-31 | 2015-03-24 | Sanofi-Aventis Deutschland Gmbh | Piston rod assembly for a drug delivery device |
-
2012
- 2012-09-27 ES ES12762612.5T patent/ES2581503T3/es active Active
- 2012-09-27 PL PL12762612.5T patent/PL2760507T3/pl unknown
- 2012-09-27 WO PCT/EP2012/069032 patent/WO2013045527A1/en not_active Ceased
- 2012-09-27 CA CA2848181A patent/CA2848181A1/en not_active Abandoned
- 2012-09-27 EP EP12762612.5A patent/EP2760507B8/en active Active
- 2012-09-27 JP JP2014532378A patent/JP6251172B2/ja active Active
- 2012-09-27 AR ARP120103599A patent/AR088084A1/es not_active Application Discontinuation
- 2012-09-27 HU HUE12762612A patent/HUE029364T2/en unknown
- 2012-09-27 US US14/346,507 patent/US9707352B2/en active Active
- 2012-09-27 DK DK12762612.5T patent/DK2760507T3/da active
-
2017
- 2017-06-13 US US15/620,993 patent/US10376650B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2581503T3 (es) | 2016-09-06 |
| US20140236096A1 (en) | 2014-08-21 |
| EP2760507B1 (en) | 2016-04-06 |
| US10376650B2 (en) | 2019-08-13 |
| JP2014527887A (ja) | 2014-10-23 |
| CA2848181A1 (en) | 2013-04-04 |
| EP2760507A1 (en) | 2014-08-06 |
| AR088084A1 (es) | 2014-05-07 |
| WO2013045527A1 (en) | 2013-04-04 |
| EP2760507B8 (en) | 2018-04-18 |
| HUE029364T2 (en) | 2017-03-28 |
| US20170281874A1 (en) | 2017-10-05 |
| JP6251172B2 (ja) | 2017-12-20 |
| US9707352B2 (en) | 2017-07-18 |
| PL2760507T3 (pl) | 2016-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2760507T3 (da) | Lægemiddelfremføringsanordning og fremgangsmåde til samling af en lægemiddelfremføringsanordning | |
| EP2854908A1 (en) | Drive mechanism for a drug delivery device and drug delivery device | |
| EP2996743B1 (en) | Assembly for a drug delivery device and drug delivery device | |
| DK2654858T3 (da) | Injektionsanordning med dosisindstillingsmekanisme med maksimaldosisstop | |
| EP2968780B1 (en) | Assembly for a drug delivery device | |
| EP2854907A1 (en) | Drive mechanism for a drug delivery device and drug delivery device | |
| US10569024B2 (en) | Assembly for a drug delivery device and drug delivery device | |
| EP2838591B1 (en) | Assembly for a drug delivery device and drug delivery device | |
| EP2766072B1 (en) | Assembly for a drug delivery device | |
| US10357613B2 (en) | Assembly for a drug delivery device | |
| EP2968781A1 (en) | Assembly for a drug delivery device | |
| EP2950857B1 (en) | Assembly for a drug delivery device | |
| HK1215551B (en) | Assembly for a drug delivery device and drug delivery device | |
| HK1195520B (en) | Assembly for a drug delivery device | |
| HK1195520A (en) | Assembly for a drug delivery device | |
| TW201325646A (zh) | 藥物傳送裝置及用於一藥物傳送裝置的方法 |